The TASKIN trial found a 12-month overall survival rate of 61.3% with vilamakitug plus standard-of-care therapy, with exploratory findings suggesting potential benefit in right-sided tumors.
|Videos|February 17, 2017
Liver-Directed Therapy in Metastatic Colorectal Cancer
Author(s)John L. Marshall, MD
John L. Marshall, MD, chief, Division of Hematology and Oncology, Medstar Georgetown University Hospital, discusses the current state of liver-directed therapy in metastatic colorectal cancer.
Advertisement
Advertisement
Related to this article
FDA approves dostarlimab for MSI-H/dMMR locally advanced rectal cancer, driving high complete responses and helping many patients avoid surgery, radiation, and chemo.
The oral KRAS G12D inhibitor VS-7375 elicited clinical responses across patients with KRAS G12D–mutant pancreatic, lung, and colorectal cancer.
The phase 2 PEGASUS trial of ctDNA-guided adjuvant therapy in high-risk stage II/III colon cancer missed its primary end point but reduced neurotoxicity.
Multiple oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.
Breakthrough targeted therapies—from KRAS and PROTACs to CAR T—plus ctDNA monitoring and personalized vaccines push earlier detection and smarter cancer treatment.
J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.
The RELIGHT study found that adding retlirafusp alfa to chemotherapy extended overall and progression-free survival in previously untreated gastric and GEJ cancers.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Selpercatinib Shows Durable Responses in Pediatric Solid Tumors
2
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
3
Male Sex, Age, and Tumor Genetics Linked to Thyroid Cancer Mortality
4
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
5